Ronald E. Savage

Ronald E. Savage

Auto-generated profile, based on publicly available information

Ronald E. Savage

ArQule, Inc., Burlington, MA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 November 2023 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
JWJennifer A. Woyach
Jennifer A. Woyach
DSDeborah M. Stephens
Deborah M. Stephens
IFIan W. Flinn
Ian W. Flinn
SBSeema A. Bhat
Seema A. Bhat
RSRonald E. Savage
Ronald E. Savage
JBJohn C. Byrd
John C. Byrd
Nemtabrutinib is an orally bioavailable, reversible inhibitor of Bruton tyrosine kinase (BTK) and C481S mutant BTK. We evaluated the safety, pharmacology, and antitumor activity of nemtabrutinib in relapsed/refractory hematologic malignancies. Forty-eight patients with chronic lymphocytic leukemia (CLL), B-cell non–Hodgkin lymphoma (NHL), or Waldenström macroglobulinemia (WM), relapsed/refractory after ≥2 prior therapies were enrolled in the open-label, single-arm, phase I MK-1026-001 study (NCT03162536) to receive nemtabrutinib 5 to 75 mg once daily in 28-day cycles. Dose finding progressed using a 3 + 3 dose escalation design. Primary endpoints were safety and the recommended phase II dose (RP2D). Among 47 treated patients, 29 had CLL, 17 had NHL, and 1 had WM. Grade ≥3 treatment-emergent adverse events occurred in 37 (89%), most commonly neutropenia (11; 23.4%), febrile neutropenia (7; 14.9%), and pneumonia (7; 14.9%). The RP2D was 65 mg daily. An overall response rate of 75% was observed in patients with CLL at 65 mg daily. Significance: This first-in-human phase I study demonstrates the safety and preliminary efficacy of nemtabrutinib in patients with relapsed/refractory B-cell malignancies. These data support further exploration of nemtabrutinib in larger clinical studies. This article is featured in Selected Articles from This Issue, p. 5

9 June 2014 in Xenobiotica
Verified
Journal Article
Closed access
PDF file
TMTakahiro Murai
Takahiro Murai
HTHideo Takakusa
Hideo Takakusa
DNDaisuke Nakai
Daisuke Nakai
EKEmi Kamiyama
Emi Kamiyama
TTTomoe Taira
Tomoe Taira
TITakashi Izumi
Takashi Izumi
1. The biotransformation and disposition of tivantinib in humans, dogs and rats was examined after a single oral administration of [14C]tivantinib. Tivantinib constituted no more than one-third of the plasma radioactivity in all species, demonstrating significant contribution of the metabolites to plasma radioactivity. The major circulating metabolites in all species were M4 and M5, hydroxylated metabolites at the benzyl position of the tricyclic ring, accounting for 19.3 and 12.2% of the AUC of the total radioactivity, respectively, in humans. 2. The majority of radioactivity was excreted to the feces via bile. Tivantinib was detected at trace levels in urine, feces and bile, demonstrating extensive metabolism prior to biliary excretion and nearly complete tivantinib absorption under fed conditions. 3. Seven metabolic pathways were identified for tivantinib and included six oxidations (M4, M5, M7, M8, M9 and M11) and one glucuronidation (M23). The major metabolic and excretory pathways were found to be common among all species. Species differences in the metabolic pathways included lactam metabolite (M8) formation in humans and dehydrogenated metabolite (M11) formation in animals. 4. None of the metabolites identified in this work are believed to significantly impact the efficacy or toxicity of tivantinib in humans.

20 May 2014 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
MTMASAYA TACHIBANA
MASAYA TACHIBANA
KPKyriakos P. Papadopoulos
Kyriakos P. Papadopoulos
LSLon S. Smith
Lon S. Smith
DMDanielle Mutz
Danielle Mutz
AMAlain C. Mita
Alain C. Mita
HZHamim Zahir
Hamim Zahir
E13528 Background: Tivantinib is an orally administered MET inhibitor currently under development as a cancer therapy. The effect of tivantinib on ECG parameters was evaluated in clinical settings. Methods: A prospective-retrospective analysis was conducted to evaluate the relationship between the plasma concentrations and change from baseline in QTc intervals. Combined PK and ECG paired data from three healthy and three cancer subject trials were analyzed using linear mixed effect modeling approach. Additionally, a phase 1, single-blind, single-sequence, placebo-controlled study (NCT01699061) was conducted in subjects with advanced solid tumors to evaluate tivantinib’s effect on QTc intervals. In this study, serial three repeated 12-lead ECG and time-matched plasma concentration data were collected over 12 hours following single and multiple doses of tivantinib at 360 mg BID. All ECG results were analyzed by a core ECG laboratory. The predefined FDA approved hypothesis was that no clinically relevant QTc...

12 January 2024
Verified
Other
Open access
JWJennifer A. Woyach
Jennifer A. Woyach
DSDeborah M. Stephens
Deborah M. Stephens
IFIan W. Flinn
Ian W. Flinn
SBSeema A. Bhat
Seema A. Bhat
RSRonald E. Savage
Ronald E. Savage
JBJohn C. Byrd
John C. Byrd
Nemtabrutinib is an orally bioavailable, reversible inhibitor of Bruton tyrosine kinase (BTK) and C481S mutant BTK. We evaluated the safety, pharmacology, and antitumor activity of nemtabrutinib in relapsed/refractory hematologic malignancies. Forty-eight patients with chronic lymphocytic leukemia (CLL), B-cell non–Hodgkin lymphoma (NHL), or Waldenström macroglobulinemia (WM), relapsed/refractory after ≥2 prior therapies were enrolled in the open-label, single-arm, phase I MK-1026-001 study (NCT03162536) to receive nemtabrutinib 5 to 75 mg once daily in 28-day cycles. Dose finding progressed using a 3 + 3 dose escalation design. Primary endpoints were safety and the recommended phase II dose (RP2D). Among 47 treated patients, 29 had CLL, 17 had NHL, and 1 had WM. Grade ≥3 treatment-emergent adverse events occurred in 37 (89%), most commonly neutropenia (11; 23.4%), febrile neutropenia (7; 14.9%), and pneumonia (7; 14.9%). The RP2D was 65 mg daily. An overall response rate of 75% was observed in patients with CLL at 65 mg daily.Significance:This first-in-human phase I study demonstrates the safety and preliminary efficacy of nemtabrutinib in patients with relapsed/refractory B-cell malignancies. These data support further exploration of nemtabrutinib in larger clinical studies.This article is featured in Selected Articles from This Issue, p. 5

12 January 2024
Verified
Other
Open access
JWJennifer A. Woyach
Jennifer A. Woyach
DSDeborah M. Stephens
Deborah M. Stephens
IFIan W. Flinn
Ian W. Flinn
SBSeema A. Bhat
Seema A. Bhat
RSRonald E. Savage
Ronald E. Savage
JBJohn C. Byrd
John C. Byrd
Supplementary Figure S1 shows mean (+SD) plasma concentrations of nemtabrutinib vs time following single (C1D1) oral doses of MK-1026 (linear and semi-log plots) nM

12 January 2024
Verified
Other
Open access
JWJennifer A. Woyach
Jennifer A. Woyach
DSDeborah M. Stephens
Deborah M. Stephens
IFIan W. Flinn
Ian W. Flinn
SBSeema A. Bhat
Seema A. Bhat
RSRonald E. Savage
Ronald E. Savage
JBJohn C. Byrd
John C. Byrd
Supplementary Figure S1 shows mean (+SD) plasma concentrations of nemtabrutinib vs time following single (C1D1) oral doses of MK-1026 (linear and semi-log plots) nM